RESOURCES FOR YOUR PRACTICE AND YOUR PATIENTS

Quick Links

Resources for Your Practice

HELPFUL LINKS FOR YOUR PRACTICE

REGISTER FOR UPDATES AND MORE

It only takes a few moments.

FIND SAMPLES & SAVINGS

Request savings offers for eligible patients and request samples.

REQUEST SAMPLES AND SAVINGS

Download and send a savings coupon offer for ANORO^*

Subject to eligibility. Restrictions apply.

DOWNLOAD COUPON

*Every download will have a unique number, so please download one coupon per patient. Please see the coupon for complete rules and eligibility.

Eligible patients may pay as little as $0 for ANORO

Savings offer valid for up to 12 uses of ANORO (30-day supplies) prior to expiration date. Not for use by Medicare or government program participants.

Subject to eligibility. Restrictions apply.

Please see the savings offer for complete rules and eligibility.

Eligible commercial patients may pay as little as $0 per 30-day prescription for ANORO ELLIPTA. Maximum savings of $190 per month between January 1, 2021 and March 31, 2021; and $150 per month at all other times for patient’s out-of-pocket cost (the amount paid after insurance deductions, if any). Any remaining out-of-pocket cost is at the patient’s expense. Eligible patients who are without insurance and fully responsible for the cost of their prescriptions will receive $100 applied to their out-of-pocket cost.

VIEW FULL ELIGIBILITY REQUIREMENTS AND RESTRICTIONS

Eligibility requirements and restrictions

ELIGIBILITY: Patients may be eligible for this offer if they have commercial insurance and insurance does not cover the full cost of the prescription or if they are not insured and are responsible for the cost of their prescriptions. Government beneficiaries; patients who are enrolled in any federal healthcare program, including patients enrolled in Medicare (Part D or otherwise), Medicaid, Medigap, Veterans Affairs (VA) or Department of Defense (DOD) programs, or TRICARE; patients who are Medicare eligible and enrolled in an employer-sponsored group waiver health plan or government prescription drug benefit program for retirees; or patients enrolled in any similar federal or state programs, including state pharmaceutical assistance programs, are NOT eligible for this offer. Further, patients CANNOT use this coupon if they are Medicare eligible. For coupon eligibility purposes, all those 65 or older will be considered Medicare eligible. If patients are government beneficiaries or Medicare eligible, they may not use this savings offer even if they elect to be processed as an uninsured (cash-paying) patient. This offer is not health insurance and is restricted to residents of the United States, Puerto Rico, and US territories. Void where prohibited by law, taxed, or restricted. Not valid in Massachusetts or California if an AB-rated generic drug is available for the product.

TERMS OF USE: Eligible commercially insured/covered patients with no restrictions (eg, step edit, prior authorization, or NDC block) and patients with a valid prescription for ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder) who present this savings card at participating pharmacies will pay as little as $0 for each covered 30-, 60-, or 90-day supply (1-3 inhalers) of ANORO. Maximum savings of $190 per month between January 1, 2021 and March 31, 2021; and $150 per month at all other times for patient’s out-of-pocket cost (the amount paid after insurance deductions, if any). If you pay cash for your prescription, or are insured and your insurance does not cover or has a managed care restriction (eg, step edit, prior authorization, or NDC block), and are not a government beneficiary or Medicare eligible, you will receive up to $100 in savings on your out-of-pocket costs for each 30-day supply for each product. This offer is valid for up to 12 uses per product, and each 30-day supply per product counts as 1 use. Other restrictions may apply. Patient is responsible for applicable taxes, if any. This offer is limited to 1 per person and is nontransferable and cannot be combined with any other coupon, free trial, or similar offer. No substitutions are permitted. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the amount received by the patient through this offer. Offer must be presented along with a valid prescription for ANORO at the time of purchase. Your acceptance of this offer must be consistent with the terms of any drug benefit plan provided to you by your health insurer. You agree to report your use of this coupon to your health insurer if required.

GSK or McKesson (on GSK’s behalf) reserves the right to rescind, revoke, or amend this offer at any time without notice. This offer may not be sold, purchased, traded, or counterfeited. Duplicates of this uniquely coded offer are invalid and not redeemable at the pharmacy. This offer is not conditioned on any past, present, or future purchase, including refills. This offer expires on 12/31/2021.

Please visit GSKforyou.com for more details.

REQUEST SAVINGS OFFERS

GSK REIMBURSEMENT RESOURCE CENTER

Find assistance with coverage, coding, and reimbursement.

VISIT REIMBURSEMENT CENTER

Call 1‑800‑745‑2967, Monday through Friday from 8:30 am to 8:00 pm ET.

GSK RESPONSE CENTER

For product questions or to report a side effect.

VISIT RESPONSE CENTER

To talk with a representative, call 1‑888‑825‑5249 or request a callback or click here to chat with an agent. Monday-Friday, 8:30 am - 5:30 pm ET. Closed Holidays.

REQUEST A REP

Have questions for a rep? Please contact a rep for the answers you need.

SUBMIT A REQUEST

ASK A MEDICAL SCIENCE LIAISON

Looking for scientific information?

CONTACT GSK US MEDICAL AFFAIRS

GSK US Medical Affairs is available by phone at 1-877-GSK-MI4U Monday-Friday, 8:00 am – 6:00 pm ET.

SEE COVERAGE IN YOUR AREA

USE THE FORMULARY FINDER

ELECTRONIC HEALTH RECORDS (EHR) RESOURCES

Make the most of your EHR system to improve quality of care.

LEARN MORE

Downloads for Your Practice

COPD Assessment Test (CAT)

This questionnaire helps patients and their healthcare providers measure the impact COPD is having on their wellbeing and daily life.

Patient Authorization Form

Work with your patients to see if GSK can assist in reimbursement. Patients will be required to sign a written release of medical information and authorization for GSK to provide patient-specific and benefit verification assistance through the Reimbursement Resource Center.

RESOURCES FOR YOUR PATIENTS

HELPFUL LINKS FOR YOUR PATIENTS

HELP PATIENTS UNDERSTAND COPD

Information, insights, and inspiration for patients to help them manage their COPD.

EXPLORE COPD.com

PRICING INFORMATION FOR ANORO

Information to help your patients better understand what they can expect to pay for ANORO.

SEE PRICING INFORMATION

SAVINGS OFFER FOR ANORO

Help your eligible patients get started with savings on ANORO.

Subject to eligibility. Restrictions apply.

SEE SAVINGS OFFER DETAILS

HOW TO USE ANORO ELLIPTA

This 2-minute video shows how to use the ANORO ELLIPTA inhaler. The video is a complement to ANORO Patient Information and Instructions for Use.

WATCH VIDEO

ANORO FAQ

Help your patients find answers to common questions about ANORO.

SEE ANORO FAQ

Access and Financial Assistance

GSKForYou is a website designed to help people who need help paying for their GSK prescription medicines.

VISIT GSKforyou.com

ASSISTANCE FOR UNINSURED PATIENTS

Explore information about the GSK Patient Assistance Program for patients who are uninsured.

GET FINANCIAL ASSISTANCE INFORMATION

ASSISTANCE FOR MEDICARE PART D PATIENTS

Find information about the GSK Patient Assistance Program for patients who are currently covered by Medicare Part D.

VIEW MEDICARE PART D REQUIREMENTS

ELIGIBILITY ASSESSMENT TOOL

Have your patients fill out a 3-step eligibility assessment tool to see if they qualify for any financial assistance programs.

VIEW ELIGIBILITY ASSESSMENT TOOL

Downloads for Your Patients

COPD Doctor Discussion Guide Checklist

Share this form with your patients to help inform the discussion about their COPD status at every visit.

ANORO Patient Brochure

Help your patients learn more about COPD and ANORO.

ANORO VIDEO LIBRARY

HOW TO USE THE ANORO ELLIPTA INHALER

The video is a complement to ANORO Patient Information and Instructions for Use.

For full instructions on how to use ANORO ELLIPTA, and other important information, please see the Instructions for Use for ANORO ELLIPTA.

INDICATION

IMPORTANT SAFETY INFORMATION

INDICATION & IMPORTANT SAFETY INFO

INDICATION

ANORO is for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ANORO is NOT for the relief of acute bronchospasm or for asthma.

ANORO is for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

ANORO is NOT for the relief of acute bronchospasm or for asthma.

ANORO is for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

ANORO is NOT for the relief of acute bronchospasm or for asthma.

ANORO is contraindicated in patients with severe hypersensitivity to milk proteins or with hypersensitivity to umeclidinium, vilanterol, or any of the excipients.

CONTRAINDICATIONS

ANORO is contraindicated in patients with severe hypersensitivity to milk proteins or with hypersensitivity to umeclidinium, vilanterol, or any of the excipients.
Use of a long-acting beta2-adrenergic agonist (LABA) without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

ANORO is contraindicated in patients with severe hypersensitivity to milk proteins or with hypersensitivity to umeclidinium, vilanterol, or any of the excipients.
Use of a long-acting beta2-adrenergic agonist (LABA) without an inhaled corticosteroid (ICS) is contraindicated in patients with asthma.

WARNINGS AND PRECAUTIONS

The safety and efficacy of ANORO in patients with asthma have not been established. ANORO is not indicated for the treatment of asthma. Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death, and in pediatric and adolescent patients, available data also suggest an increased risk of asthma-related hospitalization. These findings are considered a class effect of LABA monotherapy. Available data do not suggest an increased risk of death with use of LABA in patients with COPD.
ANORO should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD.
ANORO is NOT a rescue medication and should NOT be used for the relief of acute bronchospasm or symptoms. Acute symptoms should be treated with an inhaled, short-acting beta2-agonist.
ANORO should not be used more often or at higher doses than recommended or with another LABA (eg, salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs, like LABA.
Caution should be exercised when considering the coadministration of ANORO with ketoconazole and other known strong CYP3A4 inhibitors (eg, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased cardiovascular adverse effects may occur.
If paradoxical bronchospasm occurs, discontinue ANORO and institute alternative therapy.
Hypersensitivity reactions such as anaphylaxis, angioedema, rash, and urticaria may occur after administration of ANORO. Discontinue ANORO if such reactions occur.
Vilanterol can produce clinically significant cardiovascular effects in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms. If such effects occur, ANORO may need to be discontinued. ANORO should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines.
Use with caution in patients with narrow-angle glaucoma. Instruct patients to contact a healthcare provider immediately if signs or symptoms of acute narrow-angle glaucoma develop.
Use with caution in patients with urinary retention, especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a healthcare provider immediately if signs or symptoms of urinary retention develop.
Be alert to hypokalemia and hyperglycemia.

ADVERSE REACTIONS

The most common adverse reactions (≥1% and more common than placebo) reported in four 6‑month clinical trials with ANORO (and placebo) were: pharyngitis, 2% (<1%); sinusitis, 1% (<1%); lower respiratory tract infection, 1% (<1%); constipation, 1% (<1%); diarrhea, 2% (1%); pain in extremity, 2% (1%); muscle spasms, 1% (<1%); neck pain, 1% (<1%); and chest pain, 1% (<1%).
In addition to the 6-month efficacy trials with ANORO, a 12-month trial evaluated the safety of umeclidinium/vilanterol 125 mcg/25 mcg in subjects with COPD. Adverse reactions (incidence ≥1% and more common than placebo) in subjects receiving umeclidinium/vilanterol 125 mcg/25 mcg were: headache, back pain, sinusitis, cough, urinary tract infection, arthralgia, nausea, vertigo, abdominal pain, pleuritic pain, viral respiratory tract infection, toothache, and diabetes mellitus.

DRUG INTERACTIONS

Caution should be exercised when considering the coadministration of ANORO with ketoconazole and other known strong CYP3A4 inhibitors as increased systemic exposure to vilanterol and cardiovascular adverse effects may occur. See prior Warning and Precaution regarding CYP3A4 inhibitors.
ANORO should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval, or within 2 weeks of discontinuation of such agents, because they may potentiate the effect of vilanterol on the cardiovascular system.
Use beta‐blockers with caution as they not only block the pulmonary effect of beta‐agonists, such as vilanterol, but may produce severe bronchospasm in patients with COPD.
Use with caution in patients taking non–potassium-sparing diuretics, as ECG changes and/or hypokalemia associated with these diuretics may worsen with concomitant beta-agonists.
Avoid coadministration of ANORO with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects.

Please see full Prescribing Information, including Patient Information, for ANORO.

REFERENCES

Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis. 2011;6:573-581.
Cazzola M, Molimard M. The scientific rationale for combining long-acting β₂-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23(4):257-267.
Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472-486.
Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108(12):1752-1760.
Data on file, GSK.
Kerwin EM, Kalberg CJ, Galkin DV, et al. Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study. Int J Chron Obstruct Pulmon Dis. 2017;12:745-755.
Donohue JF, Worsley S, Zhu C-Q, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med. 2015;109(7):870-881, Appendix B.
Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538-1546.
Siler TM, Donald AC, O’Dell D, et al. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 mcg on health-related quality of life in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:971-979.
Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respir Med. 1991;85(suppl B):25-31.
Nici L, Mammen MJ, Charbek E, et al. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;201(9):e56-e69.

DEFINITIONS

CI=confidence interval; COPD=chronic obstructive pulmonary disease; FEV1=forced expiratory volume in 1 second; GOLD=Global Initiative for Chronic Obstructive Lung Disease; ICS=inhaled corticosteroid; LABA=long-acting beta2-adrenergic agonist; LAMA=long-acting muscarinic antagonist; LS=least squares; OR=odds ratio; QOL =quality of life; UMEC=umeclidinium; VI=vilanterol.

To report SUSPECTED ADVERSE REACTIONS, contact GSK at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

ANORO ELLIPTA was developed in collaboration with

The shape of the ELLIPTA inhaler is a trademark of the GSK group of companies.

Trademarks are property of their respective owners.

modal Window

RESOURCES FOR YOUR PRACTICE AND YOUR PATIENTS

Quick Links

For Healthcare Professionals:

For Your Patients:

Video Library: